Your browser doesn't support javascript.
loading
Deciphering the genetics and mechanisms of predisposition to multiple myeloma.
Went, Molly; Duran-Lozano, Laura; Halldorsson, Gisli H; Gunnell, Andrea; Ugidos-Damboriena, Nerea; Law, Philip; Ekdahl, Ludvig; Sud, Amit; Thorleifsson, Gudmar; Thodberg, Malte; Olafsdottir, Thorunn; Lamarca-Arrizabalaga, Antton; Cafaro, Caterina; Niroula, Abhishek; Ajore, Ram; Lopez de Lapuente Portilla, Aitzkoa; Ali, Zain; Pertesi, Maroulio; Goldschmidt, Hartmut; Stefansdottir, Lilja; Kristinsson, Sigurdur Y; Stacey, Simon N; Love, Thorvardur J; Rognvaldsson, Saemundur; Hajek, Roman; Vodicka, Pavel; Pettersson-Kymmer, Ulrika; Späth, Florentin; Schinke, Carolina; Van Rhee, Frits; Sulem, Patrick; Ferkingstad, Egil; Hjorleifsson Eldjarn, Grimur; Mellqvist, Ulf-Henrik; Jonsdottir, Ingileif; Morgan, Gareth; Sonneveld, Pieter; Waage, Anders; Weinhold, Niels; Thomsen, Hauke; Försti, Asta; Hansson, Markus; Juul-Vangsted, Annette; Thorsteinsdottir, Unnur; Hemminki, Kari; Kaiser, Martin; Rafnar, Thorunn; Stefansson, Kari; Houlston, Richard; Nilsson, Björn.
Afiliação
  • Went M; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.
  • Duran-Lozano L; Department of Laboratory Medicine, Lund University, SE-221 84, Lund, Sweden.
  • Halldorsson GH; Lund Stem Cell Center, Lund University, SE-221 84, Lund, Sweden.
  • Gunnell A; deCODE Genetics/Amgen, Sturlugata 8, IS-101, Reykjavik, Iceland.
  • Ugidos-Damboriena N; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.
  • Law P; Department of Laboratory Medicine, Lund University, SE-221 84, Lund, Sweden.
  • Ekdahl L; Lund Stem Cell Center, Lund University, SE-221 84, Lund, Sweden.
  • Sud A; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.
  • Thorleifsson G; Department of Laboratory Medicine, Lund University, SE-221 84, Lund, Sweden.
  • Thodberg M; Lund Stem Cell Center, Lund University, SE-221 84, Lund, Sweden.
  • Olafsdottir T; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, SW7 3RP, UK.
  • Lamarca-Arrizabalaga A; deCODE Genetics/Amgen, Sturlugata 8, IS-101, Reykjavik, Iceland.
  • Cafaro C; Department of Laboratory Medicine, Lund University, SE-221 84, Lund, Sweden.
  • Niroula A; Lund Stem Cell Center, Lund University, SE-221 84, Lund, Sweden.
  • Ajore R; deCODE Genetics/Amgen, Sturlugata 8, IS-101, Reykjavik, Iceland.
  • Lopez de Lapuente Portilla A; Department of Laboratory Medicine, Lund University, SE-221 84, Lund, Sweden.
  • Ali Z; Lund Stem Cell Center, Lund University, SE-221 84, Lund, Sweden.
  • Pertesi M; Department of Laboratory Medicine, Lund University, SE-221 84, Lund, Sweden.
  • Goldschmidt H; Lund Stem Cell Center, Lund University, SE-221 84, Lund, Sweden.
  • Stefansdottir L; Department of Laboratory Medicine, Lund University, SE-221 84, Lund, Sweden.
  • Kristinsson SY; Lund Stem Cell Center, Lund University, SE-221 84, Lund, Sweden.
  • Stacey SN; Department of Laboratory Medicine, Lund University, SE-221 84, Lund, Sweden.
  • Love TJ; Lund Stem Cell Center, Lund University, SE-221 84, Lund, Sweden.
  • Rognvaldsson S; Department of Laboratory Medicine, Lund University, SE-221 84, Lund, Sweden.
  • Hajek R; Lund Stem Cell Center, Lund University, SE-221 84, Lund, Sweden.
  • Vodicka P; Department of Laboratory Medicine, Lund University, SE-221 84, Lund, Sweden.
  • Pettersson-Kymmer U; Lund Stem Cell Center, Lund University, SE-221 84, Lund, Sweden.
  • Späth F; Department of Laboratory Medicine, Lund University, SE-221 84, Lund, Sweden.
  • Schinke C; Lund Stem Cell Center, Lund University, SE-221 84, Lund, Sweden.
  • Van Rhee F; Department of Internal Medicine V, University of Heidelberg, 69120, Heidelberg, Germany.
  • Sulem P; deCODE Genetics/Amgen, Sturlugata 8, IS-101, Reykjavik, Iceland.
  • Ferkingstad E; Landspitali, National University Hospital of Iceland, IS-101, Reykjavik, Iceland.
  • Hjorleifsson Eldjarn G; Faculty of Medicine, University of Iceland, IS-101, Reykjavik, Iceland.
  • Mellqvist UH; deCODE Genetics/Amgen, Sturlugata 8, IS-101, Reykjavik, Iceland.
  • Jonsdottir I; Landspitali, National University Hospital of Iceland, IS-101, Reykjavik, Iceland.
  • Morgan G; Faculty of Medicine, University of Iceland, IS-101, Reykjavik, Iceland.
  • Sonneveld P; Landspitali, National University Hospital of Iceland, IS-101, Reykjavik, Iceland.
  • Waage A; Faculty of Medicine, University of Iceland, IS-101, Reykjavik, Iceland.
  • Weinhold N; University Hospital Ostrava and University of Ostrava, Ostrava, Czech Republic.
  • Thomsen H; Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
  • Försti A; Department of Integrative Medical Biology, Umeå University, SE-901 87, Umeå, Sweden.
  • Hansson M; Department of Radiation Sciences, Umeå University, SE-901 87, Umeå, Sweden.
  • Juul-Vangsted A; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Thorsteinsdottir U; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Hemminki K; deCODE Genetics/Amgen, Sturlugata 8, IS-101, Reykjavik, Iceland.
  • Kaiser M; deCODE Genetics/Amgen, Sturlugata 8, IS-101, Reykjavik, Iceland.
  • Rafnar T; deCODE Genetics/Amgen, Sturlugata 8, IS-101, Reykjavik, Iceland.
  • Stefansson K; Southern Älvsborg Hospital, SE-501 82, Borås, Sweden.
  • Houlston R; deCODE Genetics/Amgen, Sturlugata 8, IS-101, Reykjavik, Iceland.
  • Nilsson B; Perlmutter Cancer Center, Langone Health, New York University, New York, NY, USA.
Nat Commun ; 15(1): 6644, 2024 Aug 05.
Article em En | MEDLINE | ID: mdl-39103364
ABSTRACT
Multiple myeloma (MM) is an incurable malignancy of plasma cells. Epidemiological studies indicate a substantial heritable component, but the underlying mechanisms remain unclear. Here, in a genome-wide association study totaling 10,906 cases and 366,221 controls, we identify 35 MM risk loci, 12 of which are novel. Through functional fine-mapping and Mendelian randomization, we uncover two causal mechanisms for inherited MM risk longer telomeres; and elevated levels of B-cell maturation antigen (BCMA) and interleukin-5 receptor alpha (IL5RA) in plasma. The largest increase in BCMA and IL5RA levels is mediated by the risk variant rs34562254-A at TNFRSF13B. While individuals with loss-of-function variants in TNFRSF13B develop B-cell immunodeficiency, rs34562254-A exerts a gain-of-function effect, increasing MM risk through amplified B-cell responses. Our results represent an analysis of genetic MM predisposition, highlighting causal mechanisms contributing to MM development.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Predisposição Genética para Doença / Polimorfismo de Nucleotídeo Único / Antígeno de Maturação de Linfócitos B / Estudo de Associação Genômica Ampla / Mieloma Múltiplo Limite: Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Predisposição Genética para Doença / Polimorfismo de Nucleotídeo Único / Antígeno de Maturação de Linfócitos B / Estudo de Associação Genômica Ampla / Mieloma Múltiplo Limite: Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article